We have located links that may give you full text access.
Predicting novel therapies and targets: Regulation of Notch3 by the bromodomain protein BRD4.
Molecular Cancer Therapeutics 2018 November 13
BACKGROUND: Systematic approaches for accurate re-purposing of targeted therapies are needed. We developed and aimed to biologically validate our Therapy Predicting Tool (TPT) for the re-purposing of targeted therapies for specific tumor types by testing the role of Bromodomain and Extra-Terminal motif inhibitors (BETis) in inhibiting BRD4 function and downregulating Notch3 signaling in ovarian cancer.
METHODS: Utilizing established ovarian cancer pre-clinical models, we carried out in vitro and in vivo studies using clinically relevant BETis to determine their therapeutic effect and impact on Notch3 signaling.
RESULTS: Treatment with BETis or siRNA mediated BRD4 knockdown resulted in decreased cell viability, reduced cell proliferation and increased cell apoptosis in vitro. In vivo with orthotopic mouse models demonstrated that treatment with BETi decreased tumor growth. Additionally, knockdown of BRD4 with doxycycline inducible shRNA increased survival up to 50% (p < 0.001). Treatment with either BETis or BRD4 siRNA decreased Notch3 expression both in vitro and in vivo. BRD4 inhibition also decreased the expression of NOTCH3 targets, including HES1. Chromatin immunoprecipitation revealed that BRD4 was present at the NOTCH3 promoter.
CONCLUSION: Our findings provide biological validation for the TPT by demonstrating that BETis can be an effective therapeutic for ovarian cancer by downregulating Notch3 expression.
IMPACT: The TPT could rapidly identify candidate drugs for ovarian or other cancers along with novel companion biomarkers.
METHODS: Utilizing established ovarian cancer pre-clinical models, we carried out in vitro and in vivo studies using clinically relevant BETis to determine their therapeutic effect and impact on Notch3 signaling.
RESULTS: Treatment with BETis or siRNA mediated BRD4 knockdown resulted in decreased cell viability, reduced cell proliferation and increased cell apoptosis in vitro. In vivo with orthotopic mouse models demonstrated that treatment with BETi decreased tumor growth. Additionally, knockdown of BRD4 with doxycycline inducible shRNA increased survival up to 50% (p < 0.001). Treatment with either BETis or BRD4 siRNA decreased Notch3 expression both in vitro and in vivo. BRD4 inhibition also decreased the expression of NOTCH3 targets, including HES1. Chromatin immunoprecipitation revealed that BRD4 was present at the NOTCH3 promoter.
CONCLUSION: Our findings provide biological validation for the TPT by demonstrating that BETis can be an effective therapeutic for ovarian cancer by downregulating Notch3 expression.
IMPACT: The TPT could rapidly identify candidate drugs for ovarian or other cancers along with novel companion biomarkers.
Full text links
Related Resources
Trending Papers
Executive Summary: State-of-the-Art Review: Unintended Consequences: Risk of Opportunistic Infections Associated with Long-term Glucocorticoid Therapies in Adults.Clinical Infectious Diseases 2024 April 11
Autoimmune Hemolytic Anemias: Classifications, Pathophysiology, Diagnoses and Management.International Journal of Molecular Sciences 2024 April 13
Clinical practice guidelines on the management of status epilepticus in adults: A systematic review.Epilepsia 2024 April 13
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app